Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development
When controlling for confounding variables, the results revealed that lifetime psychedelic use was not associated with lifetime cancer diagnosis nor hematologic cancer diagnosis. This was true for each of the three classifications of psychedelics: tryptamine (5-MeO-DIPT, AMT, DMT), lysergamide (LSD), and phenethylamine (2C-B, mescaline, MDMA, peyote, and San Pedro).
“Beginning in the late 1960s, concerns were raised by laboratory experiments that LSD and other psychedelics might damage chromosomes and potentially cause hematological cancers such as leukemia and lymphoma,” said study author Brian S. Barnett, an assistant professor of psychiatry at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University… today, most of the available evidence suggests that psychedelics do not pose a carcinogenic risk. But Barnett and his colleagues note that research in this area largely faded out with the 70s. Now that much more epidemiological data is available… this topic is particularly relevant, the authors say, in light of the ongoing discussion regarding the therapeutic potential of psychedelics.
Original Article (Psypost):
Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development
Artwork Fair Use: AlMare
Recent Comments